How longer-lasting therapies cut injection burden, boost adherence, and protect vision in AMD, DME, and RVO with ...

FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 over-enrolled (anticipated N>500), with final ...

New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

The market for treatments targeting macular degeneration, recognized as the leading cause of blindness in the elderly, is ...

Branch retinal vein occlusion (BRVO) has been reported to be the second most common vision-threatening vascular disorder of the retina after diabetic retinopathy worldwide 1,2. BRVO threatens vision, ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

Due to the large number of genes and mutations that result in inherited retinal degenerations (IRD), there has been a paucity of therapeutic options for these patients. There is a large unmet need for ...

CHICAGO -- Retinal injections for eye disease had a significant association with increased complications rates after cataract surgery, according to a large retrospective cohort study. Seven different ...

In “Durability with Aflibercept 8 mg in Retinal Vascular Diseases,” our panel explores how clinical trial data for ...